A specialized life science investment and advisory firm provides a turnkey solution for life sciences companies, spanning venture capital, corporate advisory and investment banking, through to preclinical, clinical research, development, commercialization and sales.
Headquartered in Sydney and with offices in London, Shanghai and New York, the firm has a unique business model that serves to finance and advise across the entire spectrum of the drug development cycle. The Group consists of several tech transfer and financing entities and currently manages two, one hundred million-dollar funds that focus on the biotech theme through investments realized in companies at different R&D and corporate stages.
The firm typically invests $5M-10M AUD per company, the amount varies depending on the technology and structure of investment opportunity. The firm also has the capability to structure special purpose vehicles and/or financial instruments to realize specific investments that fall out of their mandate. The science, advisory, and capital arms work in synergy with each other to further the development of the research and development cycle.
The firm seeks biologic therapeutics, theranostics, medical devices, diagnostics, genomics, medical artificial intelligence applications, bio-printing and biosensors. The main focus is in discovery to preclinical stage assets but will also review clinical stage assets.
The firm typically leads investments, has the ability to invest globally and through various structures and/or financial instruments it may remain invested for several years across the R&D cycle.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply